Toxicity of combined treatment of adjuvant irradiation and interferon α2b in high-risk melanoma patients

Melanoma Research

Volumn 17, Issue 5, 2007, Pages 304-309

  Conill, Carlos ^a,b   Jorcano, Sandra ^a   Domingo Domènech, Josep ^a   Marruecos, Jordi ^a   Vilella, Ramón ^a   Malvehy, Josep ^a   Puig, Susana ^a   Sánchez, Marcelo ^a   Gallego, Rosa ^a   Castel, Teresa ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Immunotherapy; Interferon 2b; Melanoma; Radiotherapy

Indexed keywords

ALPHA2B INTERFERON;

ADULT; AGED; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG EFFICACY; HUMAN; MELANOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INDUCED MYELITIS; RADIATION INJURY; RETROSPECTIVE STUDY; REVIEW; SKIN MANIFESTATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; INTERFERON ALFA-2B; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 34648847332     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3282c3a6ed     Document Type: Review

References (35)

1. Morton DL, Wen DR, Foshag LJ, Essner R, Cochran A. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol 1993; 11:1751-1756.
2. North JH Jr, Spellman JE. Role of sentinel node biopsy in the management of malignant melanoma. Oncology 1996; 10:1237-1242.
3. Emilia JC, Lawrence W Jr. Sentinel lymph node biopsy in malignant melanoma: the standard of care? J Surg Oncol 1997; 65:153-154.
4. Pidhorecky I, Lee RJ, Proulx G, Kollmorgen DR, Jia C, Driscoll DL, et al. Risk factors for nodal recurrence after lymphadenectomy for melanoma. Ann Surg Oncol 2001; 8:109-115.
5. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989; 124:1051-1055.
6. Byers RM. The role of modified neck dissection in the treatment of cutaneous melanoma of the head and neck. Arch Surg 1986; 121: 1338-1341.
7. Monsour PD, Sause WT, Avent JM, Noyes RD. Local control following therapeutic nodal dissection for melanoma. J Surg Oncol 1993; 54:18-22.
8. O'Brien CJ, Petersen-Schaefer K, Ruark D, Coates AS, Menzie SJ, Harrison RI. Radical, modified, and selective neck dissection for cutaneous malignant melanoma. Head Neck 1995; 17:232-241.
9. Bowsher WG, Taylor BA, Hughes LE. Morbidity, mortality and local recurrence following regional node dissection for melanoma. Br J Surg 1986; 73:906-908.
10. O'Brien CJ, Gianoutsos MP, Morgan MJ. Neck dissection for cutaneous malignant melanoma. World J Surg 1992; 16:222-226.
11. Lee RJ, Gibbs JF, Proulx GM, Kollmorgen DR, Jia C, Kraybill WG. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000; 46:467-474.
12. Ang KK, Peters LJ, Weber RS, Morrison WH, Frankenthaler RA, Garden AS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994; 30:795-798.
13. Johanson CR, Harwood AR, Cummings BJ, Quirt I. 0-7-21 radiotherapy in nodular melanoma. Cancer 1983; 51:226-232.
14. Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol 1995; 2:445-449.
15. Corry J, Smith JG, Bishop M, Ainslie J. Nodal radiation therapy for metastatic melanoma. Int J Radiat Oncol Biol Phys 1999; 44:1065-1069.
16. Houghton A, Coit D, Bloomer W, Buzaid A, Chu D, Eisenburgh B, et al. NCCN melanoma practice guidelines. National Comprehensive Cancer Network. Oncology (Huntingt) 1998; 12:153-177.
17. Ang KK, Byers RM, Peters LJ, Maor MH, Wendt CD, Morrison WH, et al. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results. Arch Otolaryngol Head Neck Surg 1990; 116:169-172.
18. Stevens G, Thompson JF, Firth I, O'Brien CJ, McCarthy WH, Quinn MJ. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000; 88:88-94.
19. Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2002; 52:964-972.
20. Ballo MT, Zagars GK, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 2004; 11:1079-1084.
21. Kardamakis D, Gillies NE, Souhami RL, Bewerley PC. Recombinant human interferon alpha-2b enhances the radiosensitivity of small cell lung cancer in vitro. Anticancer Res 1989; 9:1041-1044.
22. Hoffmann W, Blase MA, Santo-Hoeltje L, Herskind C, Bamberg M, Rodemann HP. Radiation sensitivity of human squamous cell carcinoma cells in vitro is modulated by all-trans and 13-cis-retinoic acid in combination with interferon-alpha. Int J Radiat Oncol Biol Phys 1999; 45:991-998.
23. Chang AY, Keng PC. Potentiation of radiation cytotoxicity by recombinant interferons, a phenomenon associated with increased blockage at the G2-M phase of the cell cycle. Cancer Res 1987; 47:4338-4341.
24. Stock RG, Dottino P, Jennings TS, Terk M, de Wyngaert JK, Beddoe AM, Cohen C. Enhanced radiosensitization with interferon-alpha-2b and cisplatin in the treatment of locally advanced cervical carcinoma. Gynecol Oncol 1997; 67:309-315.
25. Thomas R, Stea B. Radiation recall dermatitis from high-dose interferon alfa-2b. J Clin Oncol 2002; 20:355-357.
26. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001; 59:237-245.
27. Camidge R, Price A. Radiation recall dermatitis may represent the Koebner phenomenon. J Clin Oncol 2002; 20:4130.
28. Rogers PB, Plowman PN, Harris SJ, Arlett CF. Four radiation hypersensitivity cases and their implications for clinical radiotherapy. Radiother Oncol 2000; 57:143-154.
29. Gyorki DE, Ainslie J, Joon ML, Henderson MA, Millward M, McArthur GA. Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma: a retrospective single centre study. Melanoma Res 2004; 14:223-230.
30. Nguyen NP, Levinson B, Dutta S, Karlsson U, Alfieri A, Childress C, Sallah S. Concurrent interferon-alpha and radiation for head and neck melanoma. Melanoma Res 2003; 13:67-71.
31. Hazard LJ, Sause WT, Noyes RD. Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity. Int J Radiat Oncol Biol Phys 2002; 52:796-800.
32. Crasto S, Duca S, Davini O, Rizzo L, Pavanello IG, Avataneo T, et al. MRI diagnosis of intramedullary metastases from extra-CNS tumors. Eur Radiol 1997;7:732-736.
33. Wang PY, Shen WC, Jan JS. MR imaging in radiation myelopathy. AJNR Am J Neuroradiol 1992; 13:1049-1055.
34. Zweig G, Russell EJ. Radiation myelopathy of the cervical spinal cord: MR findings. AJNR Am J Neuroradiol 1990; 11:1188-1190.
35. Jeremic B, Djuric L, Mijatovic L. Incidence of radiation myelitis of the cervical spinal cord at doses of 5500 cGy or greater. Cancer 1991; 68:2138-2141.